Physician

Catherine Hall Van Poznak, MD

According to 2025 Medicare claims, Catherine Poznak, MD (NPI: 1225109242) practices medical oncology in the Detroit-Dearborn-Livonia, MI market, with the plurality of this provider's patient population coming from Wayne, MI. This provider's primary affiliated billing organization is REGENTS OF THE UNIVERSITY OF MICHIGAN (NPI: 1609192020; TIN: 386006309) and primary practice location at 48109-5000. Poznak is affiliated with the POM ACO (ACO ID: A1297), participating under the MSSP model.

Poznak's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 88 traditional Medicare patients, billed 255 HCPCS/CPT codes, and received $19,058 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 527 prescription claims across 136 beneficiaries totaling $629,768 in drug costs, led by Ibrance (Palbociclib). DME data shows 25 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $14,791 and ending at $19,058. Concurrently, Part D prescription costs have risen steadily, from $115,694 to $629,768. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	71	178	$14,791
2016	103	368	$41,021
2017	120	848	$117,723
2018	114	720	$101,317
2019	116	640	$77,616
2020	114	288	$18,206
2021	134	467	$36,789
2022	117	367	$29,601
2023	114	325	$25,221
2024	88	255	$19,058

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	57	226	$115,694
2016	59	244	$234,470
2017	57	241	$245,149
2018	52	126	$85,720
2019	83	319	$651,704
2020	88	336	$729,755
2021	96	367	$540,089
2022	106	406	$596,616
2023	126	460	$572,129
2024	136	527	$629,768

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$768
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	28	$3,545
2020	N/R	25	$10,034
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	16	$7,768
2024	N/R	25	$839

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	14	14	$105
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	43	76	$104
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	46	70	$65
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	17	20	$50
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	11	13	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	35	980	$559,304
Anastrozole	Anastrozole	273	20,909	$12,458
Exemestane	Exemestane	39	2,945	$11,024
Letrozole	Letrozole	28	2,480	$2,508
Tamoxifen Citrate	Tamoxifen Citrate	43	3,450	$1,354

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	14	$632
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$207

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Catherine Hall Van Poznak, MD?

Tedicare shows public-source Medicare data for Catherine Hall Van Poznak, MD (NPI 1225109242), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Catherine Hall Van Poznak, MD have ACO affiliation data?

Catherine Hall Van Poznak, MD is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297).

What billing organization is linked to Catherine Hall Van Poznak, MD?

Catherine Hall Van Poznak, MD is linked to REGENTS OF THE UNIVERSITY OF MICHIGAN (billing NPI 1609192020) in the available physician profile data.

Does Catherine Hall Van Poznak, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.